• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Ivermectin B1a

CAS No. 71827-03-7

Ivermectin B1a ( —— )

产品货号. M27454 CAS No. 71827-03-7

Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥3013 有现货
10MG ¥4447 有现货
25MG ¥7039 有现货
50MG ¥9477 有现货
100MG 获取报价 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Ivermectin B1a
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.
  • 产品描述
    Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.(In Vitro):Ivermectin B1a(0.3 μg/ml) is inactive, whereas in the case of the minor component, ivermectin B1b(0.3 μg/ml) produces 100% mortality of snails.
  • 同义词
    ——
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    σ1
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    71827-03-7
  • 分子量
    875.1
  • 分子式
    C48H74O14
  • 纯度
    >98% (HPLC)
  • 溶解度
    ——
  • SMILES
    CC[C@@H]([C@@H]1[C@@H](C)CC[C@]2(C[C@@H]3C[C@@H](C/C=C(C)/[C@@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)/C=C/C=C6CO[C@H]7[C@]\6(O)[C@H](C(O3)=O)C=C(C)[C@H]7O)O2)O1)C
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Lan Y, et al. Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain. J Med Chem. 2014 Dec 26;57(24):10404-23.
产品手册
关联产品
  • Methyl nomilinate

    Methyl nomilinate from citrus can modulate cell cycle regulators to induce cytotoxicity in human colon cancer (SW480) cells in vitro.

  • trans-4-(Trifluorome...

    trans-4-(Trifluoromethyl)cinnamic acid is a photosensitizing compound. It is used as a reagent in the synthesis of various compounds, such as heterocyclic compounds and pharmaceuticals.

  • RC-3095 (TFA)

    RC-3095 is a bombesin/gastrin-releasing peptide (BN/GRP) antagonist with potential anticancer activity.